Citation:Niemoeller OM, Pöllinger B, Niyazi M, Corradini S, Manapov F, Belka C, et al 2013

From Cancer Guidelines Wiki

Citation


Niemoeller OM, Pöllinger B, Niyazi M, Corradini S, Manapov F, Belka C, et al. Mature results of a randomized trial comparing two fractionation schedules of high dose rate endoluminal brachytherapy for the treatment of endobronchial tumors. Radiat Oncol 2013 Jan 7;8(1):8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23289530.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the clinical benefit of radiotherapy to the lung primary in stage IV NSCLC?Associate Professor Shalini Vinod MBBS MD FRANZCRcompleted
What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy and who do not have a mutation for targeted therapy?Dr Margot Lehman MBBS FRANZCR GDPcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the clinical benefit of radiotherapy to the lung primary in Stage IV NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the clinical benefit of radiotherapy to the lung primary in Stage IV NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. Emma.dickins/Sandbox
  2. What is the clinical benefit of radiotherapy to the lung primary in stage IV NSCLC?